^
    8ms
    IDHENTIFY: An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation (clinicaltrials.gov)
    P3; Active, not recruiting --> Completed
    Trial completion
    |
    IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • UGT1A1 (UDP glucuronosyltransferase family 1 member A1)
    |
    IDH2 mutation • UGT1A1*1*1 • UGT1A1 mutation
    |
    Abbott RealTime IDH2
    |
    cytarabine • azacitidine • Idhifa (enasidenib) • hydroxyurea
    10ms
    IDHENTIFY: An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation (clinicaltrials.gov)
    P3; Trial completion date: Dec 2023 --> Mar 2024
    Trial completion date
    |
    IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • UGT1A1 (UDP glucuronosyltransferase family 1 member A1)
    |
    IDH2 mutation • UGT1A1*1*1 • UGT1A1 mutation
    |
    Abbott RealTime IDH2
    |
    cytarabine • azacitidine • Idhifa (enasidenib) • hydroxyurea
    over2years
    IDHENTIFY: An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation (clinicaltrials.gov)
    P3, N=319, Active, not recruiting, Celgene | Trial completion date: Dec 2022 --> Dec 2023
    Trial completion date
    |
    IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • UGT1A1 (UDP glucuronosyltransferase family 1 member A1)
    |
    IDH2 mutation • UGT1A1*1*1 • UGT1A1 mutation
    |
    Abbott RealTime IDH2
    |
    cytarabine • azacitidine • Idhifa (enasidenib) • hydroxyurea